Treatment failure was evaluated by clinical manifestations (weight loss, appearance or re-occurrence of opportunistic infections or WHO clinical stage III and IV), immunological tests (CD4 count below pre-treatment level, or increased <50% of the values during treatment), viral load measurements, hemato-biology tests to monitor ARV drug toxicity.